共 138 条
[1]
Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]
Ferlay J(2013)Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 138-148
[3]
Siegel RL(2014)Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 424-433
[4]
Laversanne M(2004)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502-1512
[5]
Soerjomataram I(2008)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26 242-245
[6]
Jemal A(2010)Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet (London, England) 376 1147-1154
[7]
Ryan CJ(2021)A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer Eur Urol 80 82-94
[8]
Smith MR(2021)Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort J Nucl Med 19 825-833
[9]
de Bono JS(2018)[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Lancet Oncol 61 857-865
[10]
Molina A(2020)Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase ii prospective trial of (177)Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer J Nucl Med 397 797-804